Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.

Journal of the National Cancer Institute - 1 Jul 2014

Lee Siow Ming, Lewanski Conrad R, Counsell Nicholas, Ottensmeier Christian, Bates Andrew, Patel Nirali, Wadsworth Christina, Ngai Yenting, Hackshaw Allan, Faivre-Finn Corinne

Abstract excerpt

BACKGROUND: Median survival of non-small cell lung cancer (NSCLC) patients with brain metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) followed by maintenance erlotinib in patients with untreated brain metastases, given the potential radiosensitizing properties of erlotinib and its direct effect on brain metastases and systemic activity. METHODS: Eighty NSCLC patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Double-Blind Method

Share to Erlotinib Hydrochloride

Share to Kaplan-Meier Estimate

Share to Quinazolines

Share to Recovery of Function

Source

Open in PubMed Open full text

Identifiers

PMID: 25031274
DOI: 10.1093/jnci/dju151
PMCID: PMC4112798

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.PMID 25031274Read ↗

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.Semantic proximity Read ↗

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.Semantic proximity Read ↗

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.Semantic proximity Read ↗

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.Semantic proximity Read ↗

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.Semantic proximity Read ↗

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.Semantic proximity Read ↗

The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.Semantic proximity Read ↗

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.